POST Online Media Lite Edition



 

Tribute Pharma Canada Q2 total revenues increased 59.1%

Staff writer |
Tribute Pharmaceuticals Canada announced its operational and financial results for the second quarter ended June 30, 2015.

Article continues below






Unless otherwise indicated, all dollar amounts are in Canadian dollars.

Total revenues for the three month period ended June 30, 2015 increased by 59.1% to $6,429,500 compared to $4,041,300 in 2014. The increase in revenue was attributable to an increase in other domestic product sales of $2,170,800 or 177.9% and international product sales of $613,600 or 171.5%.

For the six month period ended June 30, 2015 total revenues increased by 59.6% to $12,021,800 compared to $7,534,800 for the same period in 2014. The increase in revenue was attributable to an increase in other domestic product sales of $4,037,600 or 206.5% and an increase in international product sales of $619,200 or 75.3%.

Excluding non-operating expenses of $7,898,700 for the three month period ended June 30, 2015 (2014 - $3,735,000 loss), the loss from operations was $920,900 compared to the prior period of $665,800.

Loss from operations excluding amortization for the three month period ended June 30, 2015 was $32,300 compared to a loss in the same period in the prior year of $369,200, which represents a decrease of $336,900 or 91.3%.

The net loss before taxes for the six month period ended June 30, 2015 was $14,001,100 compared to a loss of $7,689,000 for the same period in the prior year.


What to read next

Alliance Pharma H1 revenue increased 104%, EBITDA up 109%
Sinclair IS Pharma revenues up 19.4%, will sell non-aesthetics business
Forward Pharma Q3 net loss $15.8 million, $0.34 per share